World EPA Congress 2021 Agenda

Amsterdam, 13 - 15 April 2021

Schedule

Create your personal agenda –check the favourite icon

Apr 1309:55
Conference pass

Chair’s Opening Remarks

Keynotes
Meindert Boysen, Deputy Chief Executive and Director of the Centre for Health Technology Evaluation, National Institute for Health and Care Excellence
Apr 1310:00
Conference pass

Future-proofing strategic & operational pricing?

Keynotes
Ana Plata, Global Head of Pricing, UCB
Apr 1310:40
Conference pass

Keynote Panel Discussion: The impact of Covid-19 on Market Access and Pricing: Implications across Industry and the World, Lessons Learned and Results of the German EU-Presidency

Keynotes
Thomas Mueller, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, Federal Ministry of Health Germany
Tamir Singer, Head of Commercial Development, NHS England
Francis Arickx, Head Of The Directorate Reimbursement Of Medicines And Pharmaceutical Policy, Riziv-Inami
Anne Willemsen, Senior Project Manager, Joint Production Co-Lead Partner – Pharmaceuticals, Zorginstituut Nederland / EUnetHTA
Meindert Boysen, Deputy Chief Executive and Director of the Centre for Health Technology Evaluation, National Institute for Health and Care Excellence
Marco Rauland, Vice President Global Market Access & Pricing Strategic Planning, Merck Group
Sandro Cesaro-Tadic, Head Pricing I8 And Product Pricing Strategies, Roche
Hassan Bruneo, Head of Market Access, Pricing & Policy CEMEA, Alnylam Switzerland Gmbh
Apr 1311:40
Conference pass

Panel Discussion: Making Real-World Evidence more useful for Regulatory Agencies and HTAs

RWE and Capability-building
Gilles Ducorroy, Head of RWE Services, Novartis
Erwin De Cock, Executive Director, Clinical Engagement, Syneos Health
Pier Paolo Olimpieri, Data Analyst Coordinator, Monitoring Registries Office, AIFA
Madhusudan Kabra, Director, Evidence Generation, Otsuka Pharmaceutical
Enkeleida Nikai, Head Of Real World Evidence, Senior Director At Janssen Europe, Middle East And Africa (Emea), Janssen Pharmaceutical
Anjan Chatterjee, Senior Vice President - Global Head, Medical Affairs, Insmed Incorporated
Elena Lungu, Manager Of Policy Development, Government of Canada
Antje Behring, Head of Pharmaceuticals Department, G-BA
Mario Ouwens, Group Director Medical & Payer Evidence Statistics, Astra Zeneca
Apr 1311:40
Conference pass

Insight from industry: Value-based Contracting in the Netherlands

Pricing & Market Access
Jolanda Koenders, Head Of Patient Value And Access, Takeda
Apr 1311:40
Conference pass

Exploring proposed financial models for gene therapies in ultra-rare diseases in South America

Rare Diseases
Marcelo Sal, Head of Market Access and Pricing, South Cone of South America, PTC Therapeutics
Apr 1312:00
Conference pass

Is personalised medicine sustainable? What should be considered to ensure long term sustainability and access?

Rare Diseases
David Alderson, Director, Cogentia Healthcare Consulting
Apr 1312:20
Conference pass

Selective contracting to improve patient access

Pricing & Market Access
Fabrizio Zucca, Director Market Access Dach, Intercept Pharmaceuticals Inc
Apr 1312:20
Conference pass

Sustainability from a biotech perspective: Money never sleeps

Rare Diseases
Julien Patris, Country Manager Belgium & Luxembourg // Director Market Access & Policy CEMEA, Alnylam
Apr 1312:40
Conference pass

Latest developments in RWE in Germany: Innovative & Legislative Considerations

RWE and Capability-building
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Kevin Rieger, Head Of Public And Governmental Affairs Dach, Ipsen Pharma Gmbh
Apr 1312:40
Conference pass

Panel Discussion: Exploring International Reference Pricing for Pharmaceuticals and will this model succeed in the US?

Pricing & Market Access
Sylvie Greneche, Global Head of Market Access, General Medicines, Sanofi
Alex Bastian, Vice President, Value And Market Access, Galapagos NV
Juan Roman, Vice President, Global Market Access, HEOR and Pricing, Krystal Biotech
Bertrand Tardivel, General Manager, Frehel/ContrAST
Robert Orzechowski, Chief Operating Officer, Lancaster Cancer Centre
Jaime Espin, Professor, Andalusian School Of Public Health
Gustavo Saraiva Dos Anjos, Global Market Access Director For Biologics, GlaxoSmithKline
Erin Mistry, SVP, Head of Payer Strategy, Gov’t Affairs and Trade Relations, CorMedix Inc
Apr 1312:40
Conference pass

Comparative overview of patient access to orphan drugs across Europe

Rare Diseases
Giovanni Tafuri, Director, International Pricing & Reimbursement and Policy Strategy, Apellis Pharmaceuticals
Apr 1313:00
Conference pass

Evidence generation in Europe - How valuable is the French National administrative health data (SNDS)?

RWE and Capability-building
Nadia Quignot, Director, Decision Analytics & Real World Evidence, Certara
Apr 1313:20
Conference pass

The use of registry data for HTA submissions and beyond

RWE and Capability-building
Helene Chevrou-Severac, HEOR Director, Alexion
Apr 1313:20
Conference pass

Insights from INESSS on the challenge of assessing value of rare disease treatments?

Rare Diseases
Luc Boileau, Chairman And Chief Executive Officer, INESSS
Apr 1313:40
Conference pass

Capability building for RWE

RWE and Capability-building
Elena Panitti, Global Rwe Capability Building Lead, Novartis
Angelina Irizari Policarpio, Head of HEOR and RWE Field Communications Team, Eisai
Apr 1313:40
Conference pass

Understanding access to MedTech innovations and the journey for companies

Pricing & Market Access
Marie Theres Schmidt, Director Market Access And Government Affairs, Edwards Lifesciences
Apr 1313:40
Conference pass

Panel Discussion: Exploring the role of patient advocacy and engagement in rare diseases

Rare Diseases
Sheela Upadhyaya, Associate Director Highly Specialised Technologies, National Institute for Health and Care Excellence
Isabelle Ganache, Director of Bureau for Methodologies and Ethics, INESSS
Gundula Schneidewind, Head Ethics And Compliance, Europe And Canada, Takeda
Lara Pippo, Head Of Market Access, CSL Behring
Josie Godfrey, Director, JG Zebra Consulting
Shirin Rizzardo, Director of Specialty Medicines, Ministry of Health, British Columbia
Omar Dabbous, Vice President, Global Heor and Rwe, AveXis Inc
Apr 1314:20
Conference pass

Harnessing real-world data and advanced analytics for value assessment

RWE and Capability-building
Bernard Hamelin, Global Head Of Medical Evidence Generation, Sanofi
Apr 1314:20
Conference pass

Considerations in launching advanced diagnostics in Europe: Myriad’s myChoice HRD CDx

Pricing & Market Access
Benjamin Gannon, Vice President International Access, Policy And Advocacy, Myriad genetics
Karsten Berndt, International HTA Lead, Myriad Genetics GmbH
Apr 1314:55
Conference pass

Chair’s Opening Remarks

Keynotes
Mary Lynne Van Poelgeest-Pomfret, President, President of the World Federation for Incontinence and Pelvic Pain - WFIP
Apr 1315:00
Conference pass

Interview: Achieving greater cooperation between stakeholders to improve outcomes for the patient

Keynotes
Ryan Saadi, CEO, Tevogen Bio
Mary Lynne Van Poelgeest-Pomfret, President, President of the World Federation for Incontinence and Pelvic Pain - WFIP
Apr 1315:40
Conference pass

Keynote Panel Discussion: Understanding what value truly means for pharma, payers, HTAs and patients and how we can bridge the gaps

Keynotes
Martin Schuchardt, Global Market Access Lead, Almirall
Saira Jan, Vice-President & Chief Pharmacy Officer, Blue Cross Blue Shield of New Jersey
Trevor Richter, Director, Pharmaceutical Reviews, CADTH
Nuriya Musina, Head Of Development, Federal State Budgetary Institution, The Center For Healthcare Quality Assessme, Ministry of Health Russian Federation
Mary Lynne Van Poelgeest-Pomfret, President, President of the World Federation for Incontinence and Pelvic Pain - WFIP
Mike Crosher, Managing Director, Chugai Pharma UK
Adam Kundzewicz, Global Head of Strategic Market Access Initiatives, Boehringer Ingelheim

Create your personal agenda –check the favourite icon

Apr 1409:55
Conference pass

Chair’s opening remarks

Keynotes
Navin Joshi, Global Head of Pricing and Access Capabilities, GlaxoSmithKline
Apr 1410:00
Conference pass

Outcomes-based healthcare: the role of value-based partnerships and RWE in improving access for rare disease patients

Keynotes
Mercedes Echauri, Head Of International Access Innovation, Takeda
Apr 1410:20
Conference pass

Opportunities for Accelerated Access

Keynotes
Oliver Leatham, VP, Global Head of Commercial Strategy and EU Value & Access, Certara
Apr 1410:40
Conference pass

Keynote Panel Discussion: Risk-sharing arrangements: Are they improving patient access to new medicines?

Keynotes
Oleksandra Oleshchuk, Head of Committee, EML Committee of Ukraine
Oliver Leatham, VP, Global Head of Commercial Strategy and EU Value & Access, Certara
Wim Goettsch, Special Hta-Advisor, Zorginstituut
Alexis Serlin, Head, Asia Cluster, Novartis
Valentin Dodonov, Head of Market Access, BIOCAD
Laura Guarga, Consultant of Pharmacoeconomic Department, CatSalut
Amer Omar, Head of Access & Reimbursement EMEA Neuroscience - Rare & Genetic Disease, Lupin
Navin Joshi, Global Head of Pricing and Access Capabilities, GlaxoSmithKline
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Apr 1411:40
Conference pass

Panel Discussion: The impact of a Pandemic on Health Technology Assessment

HTA
Goedele Van Haasteren, Hta Specialist, Swiss Federal Office of Public Health
Michele de Guise, Scientific Vice-President, INESSS
Gustavo Saraiva Dos Anjos, Global Market Access Director For Biologics, GlaxoSmithKline
Mark Macgregor, Medical Director and Chair, New Drugs Committee, Scottish Medicines Consortium, Golden Jubilee National Hospital
Filippo Drago, Full Professor of Clinical Pharmacology, University of Catania
Helene Chevrou-Severac, HEOR Director, Alexion
Apr 1411:40
Conference pass

The evolution of risk sharing models for gene therapies and where to next?

Advanced Therapies
Gomathi Kaliappan, Health Systems Strategy Leader - Global Access, Roche
Apr 1411:40
Conference pass

Exploring the world of “Implementation Science” and what it means for value

Value
Melvin Olson, Global Head Rwd Strategy And Innovation, Novartis Pharma
Apr 1412:00
Conference pass

Pricing & Access Challenges in the absence of data – Gene therapies, Rare Diseases, & Oncology

Advanced Therapies
Chris Teale, Vice President Market Access, Ipsos MORI UK Ltd
Apr 1412:20
Conference pass

Evolving access policy for cell and gene therapies

Advanced Therapies
Matt Slabbert, Global Head, Value & Access Policy, Bayer Pharmaceuticals
Apr 1412:20
Conference pass

What is the role of AI in generating value?

Value
Andrea Mantovani, Former Market Access Executive, Independent
Apr 1412:40
Conference pass

What to look out for from European HTAs: Latest insight

HTA
Paolo D'Agostino, EU Market Access Lead, Seqirus
Apr 1412:40
Conference pass

Panel Discussion: How is patient centricity and RWE shaping access to cell & gene therapies?

Advanced Therapies
Paolo Morgese, EU Director Market Access & Member Relations, Alliance for Regenerative Medicine
Thomas Bols, Head of Government Affairs and Public Policy, EMEA & APAC, PTC Therapeutics
Nanxin (Nick) Li, Senior Director and Head, Health Economics and Outcomes Research (HEOR), uniQure
Daria Tolkacheva, Head of Health Economics, BIOCAD
Igor Rudychev, Vice President, Enterprise Analytics, Horizon Therapeutics
Ed Pezalla, Former Vice President, National Medical Director For Pharmaceutical Policy And Strategy, Aetna; a CVS Pharmacy Health Company
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Apr 1412:40
Conference pass

New times, old strategies: Government-Pharmaceutical Industry Agreements in Portugal

Government Affairs
Diogo Teixeira Pereira, Policy Analyst - Office for International Relations and Development, Infarmed
Apr 1413:20
Conference pass

Introduction of new reimbursement regulation in Poland (medical fund) for highly innovative medicinal products

HTA
Dominik Dziurda, Head Of Health Services Division, AOTMiT
Apr 1413:20
Conference pass

The role of government in market access: Understanding the wider context

Government Affairs
Bart Van Den Daele, External Affairs Director, Gilead Sciences
Apr 1413:40
Conference pass

Access and Health Technology Assessment in Brazil

Payer and HTA Engagement & Strategy
Luciene Fontes Schluckebier Bonan, Innovation and HTA General Coordinator, Ministry of Health - Brazil
Jonas Sertorio, Innovation and HTA Consultant, Ministry of Health - Brazil
Apr 1413:40
Conference pass

Huge opportunities big challenges: Navigating the pharmaceuticals landscape in China

China & Developing Nations
Samuel Taylor, Emerging Markets Strategic Pricing Lead, Pfizer
Apr 1413:40
Conference pass

Panel Discussion: What can be done to improve collaboration between patients and pharma?

Patient Advocacy
Dawn Torrence Ireland, President And Founder, C.H.E.R.U.B.S.
Clare Hague, Therapy Area Market Access Lead, Hematology, Janssen Pharmaceutical
Elizabeth Johnson, Lead Biologics Coordinator, Allergy Partners, P.A.
Nadia Bodkin, Founding member, Rare Advocacy Movement
Gina Ewy, Head Of Global Market Access, Hansa Biopharma
Edmund Lim, Executive Director, We CARE Journey
Ulrike Jacobi, Head Of External Affairs And Market Access, Amgen
Alfredo Gracia, Market Access Manager Spain, baxter
Apr 1414:20
Conference pass

Service changes to the Centers for Medicare and Medicaid and the implications for commercial payers

Payer and HTA Engagement & Strategy
Erin Mistry, SVP, Head of Payer Strategy, Gov’t Affairs and Trade Relations, CorMedix Inc
Apr 1414:20
Conference pass

My Child Matters: Improving child cancer survival in the developing world

China & Developing Nations
Valerie Faillat, Head of Sanofi Espoir Foundation, Sanofi
Apr 1414:55
Conference pass

Chair’s Opening Remarks

Keynotes
Lisette Kaskens, Senior Global Market Access Manager, Advanced Accelerator Applications
Apr 1415:00
Conference pass

15 years: The impact and potential of biosimilars

Keynotes
Isabell Remus, Head Biopharmaceuticals Europe, Sandoz
Apr 1415:20
Conference pass

Creating Operational and Cost Efficiencies in Long term Follow Up Studies

Keynotes
Alastair Macdonald, Senior Vice President Of Real World And Late Phase, Syneos Health
Apr 1415:40
Conference pass

Keynote Panel Discussion: Accelerating Access to treatments for Rare Diseases

Keynotes
Diego Ardigo, Head of R&D, Global Rare Diseases, Chiesi Farmaceutici SpA
Michael Muller, Head Of Market Access, Western Europe, Sun Pharma
Lisette Kaskens, Senior Global Market Access Manager, Advanced Accelerator Applications
Detlev Parow, Head Pharmaceutical Department, DAK-Gesundheit
Kevin Rieger, Head Of Public And Governmental Affairs Dach, Ipsen Pharma Gmbh
Adam Plich, Managing Director, Plich Advisory
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Ines Alves, President, ANDO Portugal

Create your personal agenda –check the favourite icon

Apr 1512:00
Conference pass

Understanding the role of AI based products to support medical decision-making and HTA analysis

Industry Showcase
Aletta de Beer, Product Owner Intensive Care, Pacmed
Apr 1512:00
Conference pass

Experience in Multi-Payer Negotiations: Canada’s pan-Canadian Pharmaceutical Alliance

HTA & Payer Showcase
Dan McLean, Senior Manager, Pan-Canadian Pharmaceutical Alliance Office
Daniel Sperber, Senior Economist, Pan-Canadian Pharmaceutical Alliance Office
Apr 1512:00
Conference pass

Market access opportunities and challenges for repurposed medicines during the Pandemic

Spotlight Session
Catarina Lopes Pereira, Global Market Access Manager, Medac
Apr 1512:10
Conference pass

Exploring value-added medicines

Industry Showcase
Maja Sercic, Policy & Science Manager, Medicines for Europe
Apr 1512:10
Conference pass

Key insight on the newly established HTA in Saudi Arabia

HTA & Payer Showcase
Mostafa Alabed, Health Economics Analyst, Evaluation and Impact Measurement Unit, Ministry Of Health - Kingdom Of Saudi Arabia
Apr 1512:10
Conference pass

Pricing of Orphan Drugs: Pricing of orphan drugs in oncology and rare diseases

Spotlight Session
Mark Nuijten, Chief Executive Officer, A2M - Minerva
Apr 1512:20
Conference pass

Value-based pricing for rare diseases in a changing US market environment

Industry Showcase
Jenny Ebert, National Account Director, Ascendis Pharma
Diann Potestio, SVP Market Access, Reimbursement & Channel Strategy, Acadia Pharmaceuticals Inc.
Apr 1512:20
Conference pass

The evolution of pharmaceutical policies in Turkey

HTA & Payer Showcase
Kagan Atikeler, Market Access Manager, Sanofi-Aventis Turkey
Apr 1512:20
Conference pass

Understanding the patient’s needs during the HTA journey

Spotlight Session
Jost Leemhuis, Head Of Safety Science, Roche
Apr 1512:30
Conference pass

Evidence synthesis for HTA in Russia

Industry Showcase
Valeriia Sokolova, Health Economics Manager, BIOCAD
Vladimir Mladov, HTA Manager, BIOCAD
Apr 1512:30
Conference pass

HTA journey in Ukraine: Value assessment of medicines

HTA & Payer Showcase
Oresta Piniazhko, Director, Hta Department, Ministry of Health of Ukraine
Apr 1512:30
Conference pass

Market access for gene therapies in Germany

Spotlight Session
Axel Boehnke, Director Market Access EU North, PTC Therapeutics
Apr 1512:40
Conference pass

Commercialization of digital therapeutics – pharma & startup partnerships

Industry Showcase
Ali Ciger, Commercial Director, Pain, Pfizer
Apr 1512:40
Conference pass

Latest developments for HTA in Tunisia

HTA & Payer Showcase
Mouna Jameleddine Chtioui, Director of the Health Technology Assessment Department, INEAS - TUNISIA
Apr 1512:40
Conference pass

How has COVID-19 shaped the digital landscape of the healthcare industry?

Spotlight Session
Rita Shorjian, Business Unit Director – Gulf Countries, Specialty, HCV & Oncology, AbbVie
Apr 1512:50
Conference pass

Cross-collaboration amongst procurement agencies for the Nordics: Challenges and opportunities for industry

Industry Showcase
Jesper Bjerggren, Senior Market Access Manager, Teva Denmark
Apr 1512:50
Conference pass

High-cost therapies in an era of cost containment

HTA & Payer Showcase
Laurene Redding, Former AVP Pharmaceutical Benefits and Innovation, Sun Life Financial
Apr 1512:50
Conference pass

Utilising real world data to support value-based contracting: Reflections and opportunities

Spotlight Session
Birgit Holz, Global Head of Contracting Innovation, Sanofi
Apr 1513:00
Conference pass

Developing an evidence generation strategy to meet G-BA requirements

Evidence Strategy, Patient & Clinical Outcomes
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Apr 1513:00
Conference pass

Panel Discussion: Can industry afford affordable pricing strategies?

Affordability
Michael Schroter, Partner, VIOPAS Partners
David Alderson, Director, Cogentia Healthcare Consulting
Diane Munch, Head of Global Pricing, Patient & Health Impact, Pfizer
Charles-Etienne de Cidrac, Director Of Health Insurance, AXA
Jennifer Cain Birkmose, Vice President, Global Head Of Patient Access And Community Engagement, Swedish Orphan Biovitrum
Indranil Bagchi, Senior Vice President And Head Of Global Value And Access, Novartis
Kate Dion, Value Communications Lead, 3D Communications
Apr 1513:00
Conference pass

Should technology evaluation take place before or after regulatory approval in Latin America?

Emerging Markets: Latin America
Maria Alejandra Blanc, Director - Regulatory Affairs – Region South America, AbbVie
Apr 1513:20
Conference pass

The impact of COVID-19 on the access landscape in Latin America

Emerging Markets: Latin America
Marcela Junqueira, Oncology Market Access Director - Latin America, Janssen Pharmaceutical
Apr 1513:40
Conference pass

Evidence generation for repurposed medicines

Evidence Strategy, Patient & Clinical Outcomes
Amer Omar, Head of Access & Reimbursement EMEA Neuroscience - Rare & Genetic Disease, Lupin
Apr 1513:40
Conference pass

Latest insight on use of economic evidence for reimbursement in Latin America

Emerging Markets: Latin America
Andres Pichon Riviere, Executive Director And Director Of Health Technology Assessment And Economic Evaluations, I.E.C.S.
Apr 1514:00
Conference pass

Leveraging technology to improve outcomes at a patient and clinical level

Evidence Strategy, Patient & Clinical Outcomes
Vijay Reddy, Global Market Access and Outcomes Research Leader - CCS Portfolio, GE Healthcare
Apr 1514:00
Conference pass

Panel Discussion: Exploring how we can achieve the best outcomes when negotiating managed entry agreements

Managed Entry Agreements
David Watson, Executive Director, Economic, Health and Commercial Policy, ABPI
Marco Marchetti, Director Of The National Center For Health Technology Assessment, Istituto Superiore di Sanita
Inneke Van De Vijver, Strategic Advisor - Reimbursement Pharmaceuticals, R.I.Z.I.V. I.N.A.M.I. National Health Insurance Agency
Natasa Zibelnik, Global Head Of Market Access, EUSA Pharma
Douglas Foerster, Head Market Access, Santhera Pharmaceuticals
Kärt Veliste, Chief Specialist at Department of Medicines and Medical Devices, Haigekassa Estonia
Ayman Semaan, Head of Market Access, Algorithm
Apr 1514:00
Conference pass

Latest insight on HTA in Egypt

Emerging Markets: Middle East
Zahraa Hassan, Pharmacoeconomics Unit, Egyptian drug authority
Asmaa Saad, Head of the Pharmacoeconomics unit, Egyptian drug authority
Apr 1514:20
Conference pass

Launching a global clinical outcome-based study during a pandemic

Evidence Strategy, Patient & Clinical Outcomes
Erik Van Den Berg, Chief Executive Officer, A.M. Pharma
Apr 1514:20
Conference pass

Understanding the reimbursement process in Israel

Emerging Markets: Middle East
Tomer Ben Zaken, Pricing And Alliance Manager, Takeda
Apr 1514:40
Conference pass

How is digital health improving patient outcomes in diabetes and what HTA challenges do we face

Evidence Strategy, Patient & Clinical Outcomes
Nadeem Ashraf, Head of CardioMetabolism for Medical Affairs, UK & Ireland, Boehringer Ingelheim
Apr 1514:40
Conference pass

Market Access framework and the impact of COVID-19 in the Middle East

Emerging Markets: Middle East
Sameh Abdou, Market Access & Strategic Alliance Manager Middle East & Africa, Abbott L.A
last published: 03/Mar/21 16:45 GMT

Get Involved With Evidence, Pricing and Access Congress

 

To sponsor or exhibit:


Edmond Rama
+44 (0)207 092 1052

edmond.rama@terrapinn.com

To speak:


Chris Shanks
+44 (0)207 092 1151

chris.shanks@terrapinn.com